60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study
60 Degrees Pharmaceuticals, Inc. (SXTP)
Company Research
Source: GlobeNewswire
Company engaged patients diagnosed with chronic babesiosis via social media in a nationwide naming competitionA $5K donation from the Company was split between ILADEF and GLA to recognize the winning nameB-FREE, a Phase 2 trial, will commence in early November and run for approximately 12 months WASHINGTON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today the name of its chronic babesiosis trial is the B-FREE Chronic Babesiosis Study. The B-FREE study (NCT06656351), the first in the world to evaluate a potential new therapeutic for chronic babesiosis, will run for approximately 12 months. It is a Phase 2 open-label study that will evaluate the efficacy and safety of the ARAKODA® regimen of tafenoquine over 90 days for resolution of severe fatigue, and parasite eradication in patients with chronic bab
Show less
Read more
Impact Snapshot
Event Time:
SXTP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SXTP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SXTP alerts
High impacting 60 Degrees Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SXTP
News
- 60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its price target lowered by analysts at Ascendiant Capital Markets from $3.00 to $2.80. They now have a "buy" rating on the stock.MarketBeat
- 60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of MedicineGlobeNewswire
- 60 Degrees Pharmaceuticals (NASDAQ:SXTP) was upgraded by analysts at Zacks Research to a "hold" rating.MarketBeat
- 60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- 60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results [Yahoo! Finance]Yahoo! Finance
SXTP
Sec Filings
- 11/13/25 - Form 10-Q
- 11/7/25 - Form SCHEDULE
- 11/7/25 - Form SCHEDULE
- SXTP's page on the SEC website